NEW DELHI: The multi-country solidarity trial led by the World Health Organization (WHO) has concluded that none of the four repurposed drugs it examined (Remdesivir, Hydroxychloroquine (HCQ), Lopinavir and Interferon) have any benefit for patients of Covid. -19, as indicated by overall mortality, initiation of ventilation, and length of hospital stay.
At present, the clinical management protocol for Covid-19 in India recommends the use of Remdesivir as an investigational therapy and HCQ as a reused off-label therapy for treatment.
“These regimens of Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon appeared to have little or no effect in hospitalized patients with Covid-19, as indicated by overall mortality, onset of ventilation, and length of hospital stay. The mortality findings contain most of the randomized evidence for Remdesivir and Interferon, and are consistent with the mortality meta-analyzes across all major trials, ”the Solidarity trial investigators reported.
The results of the study are under review for publication. A preprint is available from medRxiv.
The trial was conducted in 405 hospitals in 30 countries with 11,266 adults.
At present, the clinical management protocol for Covid-19 in India recommends the use of Remdesivir as an investigational therapy and HCQ as a reused off-label therapy for treatment.
“These regimens of Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon appeared to have little or no effect in hospitalized patients with Covid-19, as indicated by overall mortality, onset of ventilation, and length of hospital stay. The mortality findings contain most of the randomized evidence for Remdesivir and Interferon, and are consistent with the mortality meta-analyzes across all major trials, ”the Solidarity trial investigators reported.
The results of the study are under review for publication. A preprint is available from medRxiv.
The trial was conducted in 405 hospitals in 30 countries with 11,266 adults.
.
